Biosensors & POCT– category –
-
South Korea’s i-SENS Pioneers Connected Diabetes Care Future with Enhanced Biosensor Accuracy and CGM Innovation, Accelerating Global Expansion
i-SENS (Interview) South Korea Overview Hakhyun Nam, CEO of South Korean diagnostic medical device company i-SENS, articulated the company's vision to enhance global access to advanced diagnostic solutions through superior biosensor accu... -
From Wearables to Digital Twins: AI-Driven Biomarkers Reshape Personalized and Predictive Medicine
ceapress.org USA Overview Wearable technologies are rapidly transforming from consumer fitness devices into indispensable tools for medical research and healthcare. Continuously collecting vast physiological and behavioral data, these sy... -
Abbott’s Libre Duo 10 Day System Authorized by FDA: First US Continuous Dual Glucose-Ketone Wearable Provides Early DKA Warning for Diabetes Patients Ages 2+
Abbott & U.S. Food and Drug Administration (FDA) USA Overview Abbott's "Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System" has received FDA authorization, making it the first device in the US to continuously track ketone ... -
Wearable Biosensors Revolutionize Personal Health Monitoring in 2026: Real-time Tracking and Diverse Form Factors Enhance Chronic Disease Management
News-Medical.net UK Overview Wearable biosensors are fundamentally transforming personal health monitoring in 2026, shifting from intermittent clinical tests to continuous physiological recording. These devices enable real-time tracking ... -
Roche’s Elecsys® pTau217 Blood Test Gains FDA Clearance, Enabling Alzheimer’s Amyloid Pathology Identification in Primary Care for Individuals Aged 55+
Roche (Press Release) USA Overview Roche has announced FDA clearance for its Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test, offering a single, blood-based option for clinicians in both primary and specialty care to identify Alz... -
Roche’s PATHWAY® HER2 and VENTANA® HER2 Dual ISH Companion Diagnostics Approved by FDA for ZIIHERA® Eligibility in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
BioSpace USA Overview Roche has received FDA approval for two companion diagnostic tests, PATHWAY® HER2 (4B5) and VENTANA® HER2 Dual ISH DNA Probe Cocktail, to identify patients with HER2-positive metastatic gastroesophageal adenocarcino... -
Biosensors & POCT Weekly Report August 23, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 23, 2026 (PDF) — Download Weekly Report August 23, 2026 (PDF) — DownloadDownload 🎙 Podcast August 23, ... -
Dexcom’s Investment Outlook Brightens as G7 CGM Gains Expanded Reimbursement for Type 2 Non-Insulin Diabetes Patients
Seeking Alpha USA Overview Dexcom's investment thesis has significantly improved following expanded insurance reimbursement for its G7 continuous glucose monitoring (CGM) systems, now covering a large population of type 2 non-insulin dia... -
Dexcom EVP Kevin R. Sayer to Sell $2.4M in Company Stock by August 20, 2026
SEC Filing - Form 144 / Seeking Alpha USA Overview Dexcom, Inc. Executive Vice President Kevin R. Sayer filed a Rule 144 notice to sell 26,756 shares of common stock, approximately $2.4 million in value, with an anticipated sale date of ... -
ACS Publications Unveils Smart Wearable Optical Sensor (SWOS) for Real-time Multiplex Monitoring of Sweat Volume and pH with Chitin Nanopaper
ACS Publications USA Overview A new smart wearable optical sensor (SWOS) platform has been introduced, utilizing copper chloride/fluorescein immobilized on transparent chitin nanopaper (ChNP) to simultaneously and continuously monitor sw...
